Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

Phase 2/3 Not yet recruiting 74 enrolled University Health Network, Toronto

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Timeline

Start: 2026-01-05
Primary completion: 2027-11-30
Completion: 2027-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	14 mg	Oral

Indications

No indication recorded.